ArticleCureus2025
A Rare Presentation of Metastatic Prostate Cancer With Recurrent Malignant Ascites: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal carcinomatosis with malignant ascites is a rare and aggressive presentation of advanced prostate cancer, often linked to a poor prognosis. Here, a case of a 58-year-old African American male presenting with ascites as the initial manifestation of prostate cancer is reported. Imaging revealed peritoneal carcinomatosis with concomitant pelvic lymph nodes and bone metastases. Cytologic analysis of the ascitic fluid confirmed prostate origin. The patient underwent androgen deprivation therapy and systemic chemotherapy with docetaxel followed by cabazitaxel. Despite treatment, the disease progressed rapidly with rising prostate-specific antigen levels and recurrent ascites, and he ultimately passed away 15 months after diagnosis. A literature review of similar cases is included, highlighting the poor clinical outcome posed by this rare presentation. Currently, there are no standardized guidelines for managing malignant ascites in prostate cancer. This case underscores the importance of multidisciplinary care addressing both oncologic and social factors. Further research is warranted to elucidate the mechanisms of peritoneal dissemination, improve early detection, and develop tailored therapeutic strategies for prostate cancer presenting with malignant ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.